Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 12

Results For "acquisitions"

118 News Found

SecureKloud to list subsidiary Healthcare Triangle on Nasdaq
News | October 13, 2021

SecureKloud to list subsidiary Healthcare Triangle on Nasdaq

The company plans to raise US $ 15 million


Skanray to raise Rs 400 crore to fund its inorganic growth
News | October 12, 2021

Skanray to raise Rs 400 crore to fund its inorganic growth

Since its inception, the company has either acquired or taken a majority stake in five companies


Temasek to buy a stake in Integrace
Startup | October 05, 2021

Temasek to buy a stake in Integrace

The company claims to be a market leader in core orthopaedic and gynaecology segments like bone and joint disorders, pain management and, pregnancy and women’s nutrition


Samir Mehta of Torrent is the new President of IPA for 2021-23
Appointment | October 04, 2021

Samir Mehta of Torrent is the new President of IPA for 2021-23

Torrent is one of India's fastest-growing pharma majors


Healthium Medtech files DRHP for IPO
Startup | September 07, 2021

Healthium Medtech files DRHP for IPO

As of FY21, it is the largest independent medical device company and the second-largest company overall, in the surgical consumables market in India with a 7.91 per cent share based on the value


Manjushree Technopack set to acquire Classy Kontainers
Packaging | August 17, 2021

Manjushree Technopack set to acquire Classy Kontainers

MTL, with over 40 years of experience in packaging, caters to the requirements of the FMCG, F&B, homecare, personal care, agrochemicals, pharmaceutical, and liquor industries


Aceto acquires specialty exipients company A&C
News | April 16, 2021

Aceto acquires specialty exipients company A&C

Acquisition of A&C expands Aceto’s Western manufacturing footprint


Bayer gearing up for 2021-2030 decade
News | January 16, 2021

Bayer gearing up for 2021-2030 decade

Promising drug pipeline, focus on gene therapy and innovative digital health solutions will remain the key pillars of Bayer’s pharmaceutical business